2025 article

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang, Yaxin Liu, Yuee Teng, Xiaojia Wang, Jing Cheng, Zhongsheng Tong, Tao Sun, Min Yan, Xin Zhou, Fanfan Li, Jianyun Nie, Zhi‐Ming Shao, Changsheng Ye, Yongsheng Wang, Xiaohong Wu, Zhihua Li, Yudong Wu, Huihua Xiong, Hui Li, Lu Gan, Zhaofeng Niu, Juliang Zhang, Qingyuan Zhang, Yueyin Pan, Xinhong Wu, Yi Zhang, Weimin Xie, Yu Xiao, Jinnan Gao, Huadong Zhao, Yongmei Yin, Zhiying Qian, Sanyuan Sun, Kun Wang, Jinsong Lu, Yong Li, Xinshuai Wang, Xinfeng Yang, Yuting Wang, Quanren Wang, Erwei Song

9Citations signalées — pas une note de qualité

55Institutions déclarées

1Pays d’affiliation déclarés

Résumé indisponible : les résultats de l’étude ne doivent pas être déduits depuis son seul titre.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
Date Crossref: 01/12/2025
Éditeur: Elsevier BV
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Peking University Peking University Cancer Hospital Sichuan Cancer Hospital Sun Yat-sen University Sun Yat-sen Memorial Hospital Central South University Hunan Cancer Hospital Sun Yat-sen University Cancer Center First Hospital of China Medical University China Medical University Zhejiang Cancer Hospital First Affiliated Hospital of Henan University of Science and Technology Wuhan Union Hospital Union Hospital Tianjin Medical University Cancer Institute and Hospital Liaoning Cancer Hospital & Institute Henan Cancer Hospital Chongqing Cancer Hospital Anhui Medical University Second Affiliated Hospital of Anhui Medical University Fudan University Shanghai Cancer Center Southern Medical University Shandong Tumor Hospital Jiangsu Hengrui Medicine (China)Shandong First Medical University Jiangnan University Wuxi Fourth People's Hospital Hubei Cancer Hospital Jiangxi Provincial Cancer Hospital Tongji Hospital Huazhong University of Science and Technology The Affiliated Yongchuan Hospital of Chongqing Medical University Chongqing Medical University Yuncheng University Xijing Hospital Air Force Medical University Harbin Medical University Third Affiliated Hospital of Harbin Medical University Army Medical University Southwest Hospital Tumor Hospital of Guangxi Medical University Peking University Third Hospital Shanxi Academy of Medical Sciences Tang Du Hospital Jiangsu Provincial Hospital of Traditional Chinese Medicine Jiangsu Cancer Hospital Xuzhou Central Hospital Fudan University Zhongshan Hospital Guangdong General Hospital Second Affiliated Hospital of Guangzhou Medical University Guangdong Provincial People's Hospital Guangzhou Medical University Renji Hospital Guizhou Provincial People's Hospital

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

PARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesCancer Treatment and Pharmacology

Consulter la publication primaire DOI